Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RNTX with free AI briefings, catalyst countdowns, and dilution alerts.

RNTX · Rein Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$43.6M Cash on Hand
21.7mo Cash Runway
Follow RNTX by email Get an email when RNTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RNTX, unsubscribe in one click. Privacy

📣 What RNTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nasaruplase Gamma (LTI-01) Pleural Effusion Phase 2 · NCT04159831 Completed
LTI-03 Idiopathic Pulmonary Fibrosis (IPF) Phase 2 · NCT06968845 Recruiting
Caveolin-1-Scaffolding-Protein-Derived Peptide… Idiopathic Pulmonary Fibrosis Phase 1 · NCT04233814 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RNTX holds $43.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $6M/quarter from operations, an estimated runway of 21.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNTX files for a raise →

👥 Who Owns RNTX

Insiders 8.7% Other 5%+ holders 20% Institutions (70 holders) 52.8% Public and other holders 18.5%
HolderTypeShares% of sharesAs of
BIOS CAPITAL MANAGEMENT, LP 5%+ holder (13G) 7,797,502 9.04% 2026-05-06
Voss Capital, LP
10% owner
Insider 5,656,957 6.56% 2026-06-30
Funicular Funds, LP 5%+ holder (13G) 5,195,000 6.02% 2026-05-01
ADAR1 Capital Management, LLC Institution (13G, 5%+) 4,500,000 5.22% 2026-06-30
Lynwood Capital Management Inc. 5%+ holder (13G) 4,280,500 4.96% 2026-06-30
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT
10% owner
Insider 1,746,549 2.02% 2024-06-14
Rickenbach Josef H Von
Director · +60,675 options
Insider 62,514 0.07% 2026-05-21
James Brian Windsor
President and Chief Executive Officer, D · +667,500 options
Insider 27,046 0.03% 2026-04-30

Share count 86,267,032 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RNTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.